Thus, IFNα2 has been used to treat chronic hairy cell leukemia [34] chronic myelogenous leukemia [34], non-Hodgkin’s lymphoma in combination with chemo-therapy [34], and is used as an adjuvant to surgical restriction for the treatment of malignant melanoma [34,35]. This evidence concerns the gene IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive.